3-V Biosciences Closes Financing
3-V Biosciences Inc., developer of treatments for the Hepatitis C virus, has closed preferred stock financing providing the company with a minimum of $20 million, the company announced Thursday. Kleiner Perkins Caufield & Byers and New Enterprise Associates participated equally in the financing, the company said. 3-V Biosciences is based in Menlo Park, Calif.
5 January 2012•2 mins read
